Key Points
- CEO Alan Auerbach sold 16,938 shares on Jan. 6 at an average price of $5.84 for about $98,918, leaving him with 7,163,963 shares (a 0.24% ownership decline).
- Insider selling was broader: Auerbach sold a total of 34,950 shares across Jan. 6–7 and director Douglas M. Hunt sold 8,987 shares at similar prices, transactions that could temper investor sentiment despite large insider holdings.
- Puma's stock was up about 1.8%, with a market cap near $312 million and a PE of 8.38; the company recently beat quarterly EPS and revenue estimates, and analysts' consensus rating is a "Moderate Buy" with a $7 price target.
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) insider Douglas Hunt sold 3,973 shares of the firm's stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $5.84, for a total value of $23,202.32. Following the completion of the transaction, the insider owned 160,921 shares in the company, valued at approximately $939,778.64. This trade represents a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Puma Biotechnology Stock Up 1.8%
Shares of NASDAQ:PBYI opened at $6.20 on Friday. Puma Biotechnology, Inc. has a 52 week low of $2.58 and a 52 week high of $6.29. The stock has a market capitalization of $312.42 million, a P/E ratio of 8.38 and a beta of 1.19. The firm has a fifty day simple moving average of $5.42 and a two-hundred day simple moving average of $4.77.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its earnings results on Thursday, November 6th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.12. The company had revenue of $54.48 million during the quarter, compared to analysts' expectations of $51.00 million. Puma Biotechnology had a net margin of 17.45% and a return on equity of 36.17%. On average, analysts expect that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.
Analysts Set New Price Targets
Several research firms recently issued reports on PBYI. Weiss Ratings cut shares of Puma Biotechnology from a "buy (b-)" rating to a "hold (c+)" rating in a report on Saturday, October 25th. Wall Street Zen lowered shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Puma Biotechnology presently has an average rating of "Moderate Buy" and an average price target of $7.00.
View Our Latest Research Report on PBYI
Institutional Investors Weigh In On Puma Biotechnology
Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its holdings in shares of Puma Biotechnology by 39.7% during the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company's stock valued at $43,000 after acquiring an additional 2,290 shares during the period. CWM LLC boosted its position in Puma Biotechnology by 214.1% in the 2nd quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 6,450 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in Puma Biotechnology in the fourth quarter worth about $59,000. Cerity Partners LLC acquired a new position in Puma Biotechnology in the second quarter valued at approximately $36,000. Finally, Caprock Group LLC bought a new position in shares of Puma Biotechnology in the 3rd quarter worth $59,000. 61.29% of the stock is owned by institutional investors and hedge funds.
Puma Biotechnology News Summary
Here are the key news stories impacting Puma Biotechnology this week:
- Positive Sentiment: PBYI has moved above its 200‑day moving average, a technical breakout that can attract momentum and trend‑following buyers and supports upward pressure on the share price. Puma Biotechnology Stock Passes Above 200 Day Moving Average
- Neutral Sentiment: Puma disclosed inducement equity awards granted to new hires under Nasdaq Rule 5635(c)(4). These grants are a common hiring tool; they can create modest dilution over time but are typically not material to near‑term trading unless large. Puma Biotechnology Reports Inducement Awards
- Negative Sentiment: Insider selling by senior executives may temper sentiment: CEO Alan A. Auerbach sold a total of 34,950 shares across Jan. 6–7 at ~ $5.84–$5.88, and director Douglas M. Hunt sold 8,987 shares over the same dates at similar prices. While insiders still hold large positions, these disclosed sales can be perceived negatively by some investors as reduced insider conviction or simply personal liquidity events. Auerbach SEC Filing Hunt SEC Filing
Puma Biotechnology Company Profile
(
Get Free Report)
Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.
The company's lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
